United States
From November 21st to 25th, our team participated in the French Congress of Urology (CFU) in Paris. It was a genuine pleasure to have you on our booth and share with urologist primarily from France and across Europe. The conference program was of high quality.
Congress after congress, we see the guidelines evolving and the urological practices too. Many studies and physicians testimonials attest to the fact that MRI is increasingly used to diagnose prostate cancer, highlighting focal therapies as a viable option for patients, and urologists of tomorrow are more and more connected. Once again this year, Koelis took center stage and was featured in several scientific sessions.
Dr Gilles Pasticier organized the “Club Focal” with recent updates on focal therapy trials and registries. We were delighted to participate, alongside Dr. Peter Chiu, who presented the MRI-ultrasound fusion-guided targeted microwave ablation (TMA) of prostate cancer and shared his experience from Hong Kong. Fostine’s results were remarkable.
In another session, Dr. Louis Lenfant and the team from La Pitié-Salpêtrière (led by Pr Pierre Mozer) presented the results of a single-center study involving 1721 patients who underwent biopsy with MRI fusion on UroStation® and Koelis Trinity® systems between 2010 and 2020. The learning curves based on procedure time, detection rate, and patient feedback were analyzed, providing a robust and insightful examination of the technique’s reproducibility. Additionally, they presented an analysis of the difference in MRI/Echo volume at the time of fusion, optimizing the fusion quality and procedure precision. In essence: Look before you leap, because why settle for good when you can achieve greatness!
Finally, Dr. Peltier and the entire team from the Bordet Institute (Belgium) shared the results of an analysis on the impact of the evolution of the ISUP definition between 2014 (highest grade) and 2019 (global grade). The study, encompassing 249 patients who underwent systematic and targeted biopsies (Koelis) between 2016 and 2022 and presented with clinically significant cancer, showed improved concordance with prostatectomy specimens and enhanced diagnostic precision for our patients.
We are pleased to see that our solutions resonate with the market and are widely embraced and cited by urologists from various countries. Our commitment is to continually enhance and develop products that simplify the daily lives of urologists and radiologists, ultimately improving patient care from diagnosis to treatment. Koelis is undeniably at the forefront of driving innovation alongside the urologists of France!
